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Duration of acute kidney injury 
in critically ill patients
Christine K. Federspiel1,2, Theis S. Itenov2, Kala Mehta3, Raymond K. Hsu4, Morten H. Bestle2 
and Kathleen D. Liu5* 
Abstract 
Background: Duration of acute kidney injury (AKI) has been recognized a risk factor for adverse outcomes following 
AKI. We sought to examine the relationship of AKI duration and recurrent AKI with short-term outcomes in critically ill 
patients who were mechanically ventilated and met criteria for the acute respiratory distress syndrome.
Methods: Participants in the NHLBI ARDS Network SAILS multicenter trial who developed AKI were included in this 
analysis and divided into groups based on AKI duration. Differences in outcomes were evaluated using t test and Chi-
square test. Competing risks regression and Cox regression were used to evaluate factors associated with resolving 
AKI and recurrent AKI.
Results: In total, 238 patients were included in the study. Seventy-seven patients had short duration AKI (1–2 days), 
47 medium duration AKI (3–7 days), 87 persistent AKI (> 7 days) and 38 died during their AKI episode. Persistent AKI 
was associated with worse outcomes including increased ICU length of stay, time on the ventilator and days with 
cardiovascular failure. We found no clinical differences between patients with short and medium duration AKI, even 
when accounting for AKI severity and recurrent AKI. Patients with resolving AKI were less likely to have oliguria or 
moderate/severe ARDS on the day AKI criteria were met. Recurrent AKI was associated with poorer clinical outcomes. 
No baseline clinical factors were found to predict development of recurrent AKI.
Conclusions: In critically ill patients with sepsis-associated ARDS and AKI, the impact of short and medium duration 
AKI on clinical outcomes was modest. Persistent and recurrent AKI were both associated with worse clinical outcomes, 
emphasizing the importance of identifying these patients, who may benefit from novel interventions.
Keywords: Acute kidney injury, Intensive care, Acute respiratory distress syndrome, Sepsis
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Background
Acute kidney injury (AKI) is a common illness in criti-
cally ill patients that is associated with increased morbid-
ity and mortality [1–3]. The severity of AKI is typically 
graded by the magnitude of the serum creatinine rise 
and/or fall in urine output, and more severe AKI is asso-
ciated with poorer outcomes [4]. Recently, the duration 
of AKI has been recognized as an important risk factor 
for adverse outcomes, where short duration AKI (also 
called rapid reversal or transient AKI), typically defined 
as less than 48–72  h, has been associated with a lower 
risk of chronic kidney disease (CKD), end-stage renal 
disease (ESRD) and mortality compared to AKI of longer 
duration [4–7]. However, a recent ICU-based study dem-
onstrated that although persistent AKI was associated 
with an increased risk of in-hospital death, this relation-
ship was attenuated after accounting for AKI severity [8].
The main aim of the current study was to further exam-
ine the relationship of AKI duration with clinical out-
comes in a cohort of critically ill patients, accounting for 
AKI severity as well as for subsequent recurrent AKI. 
Given the lack of pharmacologic therapies for AKI and 
the urgent need to identify relevant patient populations 
for clinical trials, we sought to identify factors associated 
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with resolving AKI as well as risk factors for develop-
ment of recurrent AKI. For this analysis, we focused on 
patients with sepsis-associated acute respiratory distress 
syndrome (ARDS) who were enrolled in a clinical trial of 
rosuvastatin for ARDS [9].
Methods
Patient population
The Statins for Acutely Injured Lungs from Sepsis 
(SAILS) study was a randomized clinical trial conducted 
from March 2010 to September 2013 at 44 hospitals in 
the USA as part of the National Heart, Lung, and Blood 
Institute (NHLBI) ARDS Network (ClinicalTrials.gov 
NCT00979121) [9]. The trial tested the potential benefit 
of rosuvastatin on mortality in patients with sepsis-asso-
ciated ARDS. Specific inclusion and exclusion criteria 
are described elsewhere [9]. Ventilator management and 
weaning along with fluid management after shock reso-
lution were protocolized; specifically, ventilator man-
agement included a lung protective, low tidal volume 
ventilation strategy [9]. The trial was stopped early for 
futility; in the final analysis, there was no relationship of 
rosuvastatin therapy with mortality. For the SAILS study, 
the IRB at each site approved the study. The current study 
used de-identified data from the trial and was therefore 
exempt from IRB review.
Patients with known ESRD or who were on dialysis for 
AKI at study enrollment were excluded. Daily serum cre-
atinine measurements were available for days 1–14 after 
study enrollment along with the maximum serum creati-
nine value from days 14 to 28 and all measurements from 
the 48 h prior to enrollment. AKI was defined according 
to the KDIGO serum creatinine criteria [10]. Baseline 
serum creatinine was defined as the lowest serum cre-
atinine within the 48 h prior to randomization. AKI was 
defined as either a ≥ 1.5 times increase from baseline, or 
≥ 0.3 mg/dL increase during a 48-h rolling window [10]. 
We included all study participants who developed AKI 
during the first 5  days of study enrollment, to allow for 
sufficient follow-up time to ascertain AKI duration.
Duration of AKI
AKI duration was defined as the number of consecutive 
days where KDIGO AKI serum creatinine criteria were 
met over the first 7 days from the day AKI criteria were 
met.
We classified patients into four categories based on 
AKI duration: (1) resolving AKI which lasted 1–2  days 
(short duration AKI), (2) resolving AKI which lasted 
3–7  days (medium duration AKI), (3) persistent AKI, 
where AKI lasted more than 7 days and (4) death during 
the current AKI episode. Relevant cutoffs were chosen to 
allow comparison with previous studies [4, 7].
Recurrent AKI
The incidence of recurrent AKI was only examined in 
patients who had an initial episode of resolving AKI (e.g., 
short or medium duration AKI). Recurrent AKI was 
defined by KDIGO serum creatinine criteria using a roll-
ing baseline. Patients were censored at hospital discharge.
Study outcomes
Study outcomes were analyzed from the first day of AKI. 
Mortality was defined as death before hospital discharge 
up to day 30. Ventilator-free days were defined as patients 
being alive and breathing without ventilator assistance up 
to day 28. ICU-free days were defined as patients being 
alive and discharged from the ICU to up day 28. Patients 
who died before day 28 were assigned zero ventilator days 
and zero ICU-free days. To examine the effects of AKI 
duration on other organ systems, we evaluated Brussels 
cardiovascular failure-free days up to day 7 [11]. Patients 
were considered to be free from organ failure after hos-
pital discharge. For outcome analyses, we did not include 
patients who died during their AKI episode, since their 
outcome is already well known.
Statistical analysis
Categorical variables are presented as counts (%) and 
continuous variables as either median [interquartile 
range (IQR)] or mean  ±  standard deviation (SD) and 
compared by Chi-square test and t test, respectively.
We evaluated factors associated with resolving AKI 
versus persistent AKI using the proportional subdistri-
bution hazards model proposed by Fine and Gray, with 
death as a competing risk [12]. Values were missing for a 
small number of subjects in the urine output or platelet 
count variables (n =  16 and n =  3, respectively). These 
were carried forward from the prior study day.  PaO2/
FiO2 was missing in 58 subjects on the day of AKI; 57 
values were imputed using a validated nonlinear impu-
tation of  PaO2/FiO2 from  SpO2/FiO2 that was developed 
for patients with ARDS [13]. Two patients were excluded 
from the multivariate analysis due to missing data in 
 PaO2/FiO2 and vasopressor use.
In patients with an initial episode of resolving AKI 
(n = 123), we also examined the association of recurrent 
AKI with outcomes. Patients were stratified according to 
the presence or absence of recurrent AKI. Risk factors for 
recurrent AKI were examined using standard Cox regres-
sion and hazard ratios with 95% confidence intervals for 
this analysis, and the assumption of proportional hazards 
was tested using Schoenfeld residuals (data not shown).
A p value < 0.05 was considered statistically significant. 
All analyses were conducted using R software (http://
www.R-project.org/) including the “cmprsk” R-package.
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Results
Patients and outcomes
Of the 745 SAILS participants, we excluded 34 patients 
with end-stage renal disease or who were on acute dialy-
sis at ICU admission. Of the 711 remaining patients, 254 
developed AKI between study days 1 and 5, but 16 were 
excluded due to critical missing data (serum creatinine or 
use of dialysis) to form our final cohort of 238 patients 
(Fig. 1).
In the overall SAILS trial, 30-day mortality was 23.9%. 
The patients who developed AKI were in general more 
severely ill, with a higher APACHE III score at enroll-
ment, and greater use of vasopressors. In our study 
population (who developed AKI within the first 5  days 
of enrollment), 30-day mortality was 31.5%, significantly 
higher than those who were excluded from our analysis 
(p < 0.001). The median age was 54 (25–75% interquar-
tile range [IQR] 40–66); 181 (76.1%) were white and 53 
(22.3%) had diabetes (Table  1). The median number of 
days in the ICU before study enrollment was 1 (25–75% 
IQR 1–2), and the median day of AKI development was 
day 1 after study enrollment (25–75% IQR 1–3). The 
median baseline serum creatinine was 1.0  mg/dL (25–
75% IQR 0.7–1.4), and the median serum creatinine on 
the day of AKI development was 1.7 mg/dL (25–75% IQR 
1.2–2.6). One hundred and seventy-two (72.3%) subjects 
presented with KDIGO AKI stage 1, but during follow-
up 56 (23.5%) progressed to either stage 2 or 3 AKI.
Duration of acute kidney injury
Of the 238 study subjects, 76 (31.9%) experienced short 
duration AKI (1–2 days), 47 (19.7%) had medium dura-
tion AKI (3–7  days), 77 (32.4%) had persistent AKI on 
day 7, and 38 (16.0%) died during AKI. A histogram of 
patients’ AKI duration is presented in Fig. 2.
Table 1 presents baseline and AKI characteristics strati-
fied by AKI duration. The groups with short and medium 
duration AKI had similar distributions of comorbidities, 
APACHE III score at enrollment, as well as measures 
of general disease severity including platelet count, use 
of vasopressors and  PaO2/FiO2 ratio on the day of AKI 
development (p > 0.05 for listed characteristics for short 
duration vs. medium duration, data not shown). Patients 
who experienced persistent AKI or who died were sicker, 
with higher APACHE III at enrollment, greater use of 
vasopressors, lower platelet counts, and lower  PaO2/FiO2 
ratio on the day of AKI development. Patients with short 
duration or medium duration AKI presented with less 
severe AKI and had a lower maximum AKI stage, com-
pared to patients with persistent AKI.
Fig. 1 Flowchart of SAILS study participants. Patient flow in the study. Inclusion criteria in the SAILS study were development of sepsis-associated 
ARDS. Patients who developed AKI first 5 days of study enrollment were included in our study. Short duration AKI was defined as AKI duration of 
1–2 days, medium duration AKI as 3–7 days and persistent AKI as > 7 days. AKI acute kidney injury, ESRD end-stage renal disease, SAILS Statins for 
Acutely Injured Lungs from Sepsis
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Table 1 Baseline characteristics of study population stratified by AKI duration
Continuous variables are presented as median and interquartile range
AKI acute kidney injury, SAILS Statins for Acutely Injured Lungs from Sepsis, BMI body mass index, APACHE III acute physiologic and chronic health evaluation III, ICU 
intensive care unit, BP blood pressure, KDIGO kidney disease: improving global outcomes, PaO2/FiO2 ratio partial pressure arterial oxygen/fraction of inspired oxygen
SAILS patients AKI 
n = 238
Short duration AKI 
n = 76
Medium duration AKI 
n = 47
Persistent AKI n = 77 Death during AKI 
n = 38
Baseline characteristics
Age in years 54 [40, 66] 50 [40, 65] 53 [39, 65] 54 [40, 66] 58 [47, 68]
Female gender, n (%) 114 (47.9) 32 (42.1) 23 (48.9) 40 (51.9) 19 (50.0)
White race, n (%) 181 (76.1) 58 (76.3) 36 (76.6) 58 (75.3) 29 (76.3)
Hispanic or Latino, n (%) 32 (13.4) 14 (18.4) 7 (14.9) 8 (10.4) 3 (7.9)
BMI (kg/m2) 28.6 [23.6, 34.2] 28.0 [22.5, 33.3] 26.4 [22.8, 32.1] 30.5 [25.7, 34.6] 27.9 [24.0, 34.7]
Medical admission, n (%) 218 (91.6) 70 (92.1) 41 (87.2) 70 (90.9) 37 (97.4)
ICU days before study 
enrollment n (%)
1 [1, 2] 1 [1, 2] 2 [1, 3] 1 [1, 2] 2 [1, 2]
Rosuvastatin therapy, 
n (%)
120 (50.4) 33 (43.4) 19 (40.4) 46 (59.7) 22 (57.9)
Day of randomization 
APACHE III
98 [81, 121] 92 [78, 107] 91 [73, 112] 105 [89, 123] 121 [95, 139]
Comorbidities
Diabetes mellitus, n (%) 53 (22.3) 16 (21.1) 10 (21.3) 17 (22.1) 10 (26.3)
Hypertension, n (%) 112 (47.1) 35 (46.1) 20 (42.6) 35 (45.5) 22 (57.9)
Congestive heart failure, 
n (%)
16 (6.7) 2 (2.6) 5 (10.6) 8 (10.4) 1 (2.6)
Peripheral vascular 
disease, n (%)
12 (5.0) 4 (5.3) 3 (6.4) 4 (5.2) 1 (2.6)
Chronic pulmonary 
disease, n (%)
35 (14.7) 13 (17.1) 7 (14.9) 10 (13.0) 5 (13.2)
Cancer, n (%) 38 (16.0) 14 (18.4) 4 (8.5) 8 (10.4) 12 (31.6)
Day of AKI development
Study day that AKI 
developed
1 [1, 3] 2 [1, 3] 1 [1, 3] 1 [1, 2] 1 [1, 2]
Urine output (mL/kg/h) 0.78 [0.28, 1.48] 1.05 [0.70, 1.81] 1.36 [0.58, 2.87] 0.43 [0.06, 0.86] 0.31 [0.12, 0.88]
Platelets × 106/L 168 [74, 256] 204 [120, 292] 185 [115, 272] 143 [67, 220] 68 [26, 184]
Vasopressor use, n (%) 105 (44.3) 22 (28.9) 13 (27.7) 39 (51.3) 31 (81.6)
Systolic BP (mm Hg) 90 [80, 100] 94 [85, 105] 92 [82, 107] 86 [79, 98] 78 [70, 89]
PaO2/FiO2 ratio 155 [110, 220] 184 [129, 257] 192 [133, 272] 147 [106, 190] 123 [87, 151]
AKI characteristics
Baseline creatinine  
(mg/dL)
1.0 [0.7, 1.4] 0.9 [0.7, 1.4] 0.9 [0.6, 1.3] 1.2 [0.7, 1.9] 1.0 [0.7, 1.2]
Creatinine at AKI diag-
nosis (mg/dL)
1.7 [1.2, 2.6] 1.4 [1.0, 2.0] 1.4 [1.1, 2.0] 2.4 [1.6, 3.8] 1.8 [1.4, 2.4]
On dialysis, n (%) 25 (10.5) 1 (1.3) 0 (0.0) 18 (23.4) 6 (15.8)
KDIGO AKI stage at presentation
Stage 1, n (%) 172 (72.3) 72 (94.7) 40 (85.1) 35 (45.5) 25 (65.8)
Stage 2, n (%) 25 (10.5) 1 (1.3) 5 (10.6) 14 (18.2) 5 (13.2)
Stage 3, n (%) 41 (17.2) 3 (3.9) 2 (4.3) 28 (36.4) 8 (21.1)
KDIGO AKI maximum severity stage day 1–7
Stage 1, n (%) 116 (48.7) 63 (82.9) 31 (66.0) 13 (16.9) 9 (23.7)
Stage 2, n (%) 36 (15.1) 5 (6.6) 12 (25.5) 11 (14.3) 8 (21.1)
Stage 3, n (%) 86 (36.1) 8 (10.5) 4 (8.5) 53 (68.8) 21 (55.3)
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Effect of AKI duration of outcomes
Table  2 presents outcomes stratified according to AKI 
duration. There were no significant differences or observ-
able trends between the groups with short and medium 
duration AKI with regard to cardiovascular failure-
free days, ventilator-free days, ICU-free days or 30-day 
mortality. Compared to patients with persistent AKI, 
patients with short duration AKI had more cardiovas-
cular failure-free days (4.8 ± 2.3 vs. 3.2 ± 2.4, p < 0.001), 
ventilator-free days (17.6 ± 10.8 vs. 13.2 ± 10.0, p < 0.01) 
and ICU-free days (16.6 ± 10.7 vs. 10.8 ± 9.3, p < 0.01), 
but there was no difference in 30-day mortality (18.4 vs. 
20.8%, p = 0.87). Further, patients with medium duration 
AKI had more cardiovascular failure-free days (4.8 ± 2.2 
vs. 3.2 ± 2.4, p < 0.01), ventilator-free days (17.5 ± 10.7 
vs. 13.2 ± 10.0, p = 0.02) and ICU-free days (16.9 ± 9.9 
vs. 10.8 ± 9.3, p < 0.01) when compared to patients with 
persistent AKI. No difference in 30-day mortality (14.9 
vs. 20.8%, p  =  0.56) was found between patients with 
medium duration AKI and persistent AKI. There were 
no differences in duration of AKI or mortality based on 
treatment assignment to rosuvastatin or placebo (data 
not shown).
In the sensitivity analysis where only those with maxi-
mum KDIGO AKI severity stage 1 (Additional file  1: 
Table 1) were analyzed, cardiovascular failure-free days, 
ventilator-free days, ICU-free days and 30-day mortality 
were virtually the same in those with short and medium 
duration AKI, as observed in the main analysis. A very 
small number of individuals had persistent AKI that 
remained Stage 1 (n = 13), so we had very limited power 
to detect differences in outcomes between those with 
persistent AKI and those with short or medium duration 
AKI among those with Stage 1 AKI.
Factors associated with resolving AKI
We next examined factors associated with resolving AKI 
to day 7 (Table  3). In univariate analyses, higher sys-
tolic blood pressure was associated with higher rates of 
resolving AKI while oliguria, moderate/severe ARDS and 
higher serum creatinine on the day of AKI were associ-
ated with lower rates of resolving AKI and remained sig-
nificant predictors in multivariate analysis.
Fig. 2 Histogram of AKI duration. Histogram of AKI duration in 
patients included on our study (n = 238) with a 7-day follow-up. One 
hundred and eighteen patients had an AKI duration lasting less than 
7 days. Seventy-seven patients experienced AKI duration > 7 days, 
while 43 patients died during an AKI episode
Table 2 Association of AKI duration with outcomes
Cardiovascular failure was defined as the need for vasopressor or a systolic blood pressure of 90 mmHg or less. Patients who died before day 28 were assigned zero 
ventilator days and zero ICU-free days
AKI acute kidney injury, ICU intensive care unit, SD standard deviation, NS nonsignificant
Short duration 
AKI n = 76
Medium duration 
AKI n = 47
Persistent AKI 
n = 77
p value (short vs. 
medium duration 
AKI)
p value (short 
duration vs. per-
sistent AKI)
p value (medium 
duration vs. per-
sistent AKI)
Cardiovascular 
failure-free 
days to day 7 
(mean ± SD)
4.8 ± 2.3 4.8 ± 2.2 3.2 ± 2.4 0.98 < 0.001 0.001
Ventilator-free 
days to day 28 
(mean ± SD)
17.6 ± 10.8 17.5 ± 10.7 13.2 ± 10.0 0.97 0.009 0.02
ICU-free days to day 
28 (mean ± SD)
16.6 ± 10.7 16.9 ± 9.9 10.8 ± 9.3 0.85 0.001 0.001
Death in health care 
facility to day 30, 
n (%)
14 (18.4) 7 (14.9) 16 (20.8) 0.80 0.87 0.56
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Impact of recurrent AKI on outcomes and risk factors 
for recurrent AKI
We examined the incidence of recurrent AKI in those 
with an initial episode of resolving AKI. Of the 123 
subjects, 43 subjects (35.0%) met criteria for AKI again 
during in the hospital admission. When outcomes were 
examined in patients with or without recurrent AKI 
(Table  4), there were still no differences or trends in 
outcomes between those short versus medium duration 
AKI, similar to our main analysis. However, those with an 
Table 3 Factors associated with resolving AKI
Factors associated with resolving AKI, defined as an AKI duration of less than 7 days, analyzed by the proportional subdistribution hazards model proposed by Fine 
and Gray, with death as a competing risk. Two patients were excluded from the original population (n = 238) due to missing values
AKI acute kidney injury, BMI body mass index, BP blood pressure, PaO2/FiO2 ratio partial pressure arterial oxygen/fraction of inspired oxygen
n = 236 Univariate Cox regression (haz-
ard ratio)
p value Multivariate Cox regression 
(hazard ratio)
p value
HR (95% CI) HR (95% CI)
Age, per 10 year increase 0.94 0.86–1.03 0.19
Female gender 0.85 0.61–1.17 0.31
White race 1.03 0.70–1.51 0.88
Hispanic or Latino ethnic group 1.50 0.98–2.30 0.06
BMI 1.00 0.98–1.02 0.88
Diabetes mellitus 0.91 0.61–1.34 0.63
History of hypertension 0.91 0.65–1.26 0.55
Platelet count < 0.001 0.27
 > 150 × 109/L 1 1
 < 150 × 109/L 0.54 0.38–0.78 0.80 0.53–1.19
Urine output < 0.0001 0.01
 > 0.5 mL/kg/h 1 1
 < 0.5 mL/kg/h 0.31 0.20–0.47 0.53 0.32–0.87
PaO2/FiO2 ratio < 0.0001 0.001
 > 200 1 1
 < 200 0.52 0.38–0.71 0.59 0.44–0.81
Creatinine mg/dl, per unit increase 0.59 0.48–0.74 < 0.0001 0.71 0.57–0.89 0.003
Systolic BP, per 10 mm Hg increase 1.15 1.05–1.25 0.002 1.09 0.99–1.20 0.07
Vasopressor use 0.46 0.32–0.67 < 0.0001 0.91 0.59–1.41 0.68
Table 4 Association of recurrent AKI with outcomes
Cardiovascular failure was defined as the need for vasopressor or a systolic blood pressure of 90 mmHg or less. Patients who died before day 28 were assigned zero 
ventilator days and zero ICU-free days
AKI acute kidney injury, ICU intensive care unit, SD standard deviation, NS nonsignificant
*Short duration AKI without recurrent AKI vs. medium duration AKI without recurrent AKI
§ Short and medium duration AKI without recurrent AKI versus short and medium duration AKI with recurrent AKI
n = 123 No recurrent AKI p value* Recurrent AKI p  value§
Short duration AKI n = 46 Medium duration AKI n = 34 Short and medium duration 
AKI n = 43
Cardiovascular failure-free days 
to day 7 (mean ± SD)
5.1 ± 2.3 4.8 ± 2.3 0.47 4.4 ± 2.3 0.06
Ventilator-free days to day 28 
(mean ± SD)
20.4 ± 10.0 20.0 ± 9.8 0.89 12.7 ± 10.6 0.003
ICU-free days to day 28 
(mean ± SD)
19.7 ± 9.5 19.4 ± 8.7 0.89 11.4 ± 10.7 0.001
Death in health care facility to 
day 30, n (%)
5 (10.9) 4 (11.8) 1.00 12 (27.9) 0.04
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initial episode of short and medium duration AKI with-
out recurrent AKI had better outcomes than those who 
experienced an episode of recurrent AKI, with more ven-
tilator-free days (mean ± SD, 20.2 ± 9.8 vs. 12.7 ± 10.6, 
p  =  0.003), ICU-free days (mean  ±  SD, 19.5  ±  9.1 vs. 
11.4 ± 10.7, p = 0.001), and lower 30-day mortality (11.2 
vs. 27.9%, p = 0.039). Similar results were observed when 
the analysis was restricted to patients with a maximum 
of stage 1 AKI and stratified according to the presence or 
absence of recurrent AKI (data not shown). However, no 
baseline factors were found to be significantly associated 
with development of recurrent AKI in the univariate Cox 
regression analysis (Additional file 2: Table 2).
Discussion
AKI remains a disease with poor outcomes for which 
there are no treatments, apart from supportive care. 
Duration of AKI has been recognized as an important 
factor associated with outcomes following AKI. It has 
been implied that differences in AKI duration may repre-
sent distinct phenotypes of AKI due to etiology of injury, 
but these views are still to be confirmed at a mechanistic 
level [6, 8, 14]. In this study, we explored the effect of AKI 
duration on outcomes in a cohort of critically ill patients 
with sepsis-associated ARDS.
We found that 31.9% of the patients had an AKI dura-
tion of less than 48 h, demonstrating that short duration 
AKI is very common. Consequently, to further examine 
the effect of short duration AKI on outcomes, we divided 
those with resolving AKI into two subgroups of short 
and medium duration AKI. Although we expected the 
patients with short AKI to have lower severity of illness 
than patients with medium duration AKI, there were no 
differences between the groups with regard to comor-
bidities, AKI severity or general disease severity meas-
urements. Patients with short duration AKI had similar 
outcomes compared to the patients with medium dura-
tion AKI, and these results were confirmed in two subse-
quent analyses. First, to examine whether the results were 
due to differences in AKI severity, we restricted our anal-
ysis to those whose maximum AKI severity was Stage 1. 
Second, we hypothesized that those with short duration 
AKI might have an increased risk of adverse outcomes 
due to recurrent AKI episodes and therefore stratified 
our analysis by the presence or absence of recurrent AKI. 
Again, there were no differences in outcomes, suggest-
ing that short duration AKI is not associated with bet-
ter outcomes than medium duration AKI in critically ill 
patients.
A significant proportion of patients (32.4%) had per-
sistent kidney failure lasting 7 or more days, and these 
patients experienced poorer clinical outcomes includ-
ing increased length of ICU stay, time on the ventilator 
and days with cardiovascular failure. This emphasizes 
the importance of identifying high-risk patients who 
may benefit the most from early interventions and novel 
treatments. Along the same lines, those with quick and 
spontaneous resolving AKI may dilute trials and perhaps 
should not be the target of new treatment trials. Here, we 
found that lack of oliguria, lower serum creatinine on the 
day of AKI and having mild ARDS were associated with 
increased likelihood of resolving AKI.
Patients with recurrent AKI were found to have worse 
short-term outcomes. It has previously been reported 
that recurrent AKI episodes are associated with an 
increased risk of CKD progression and other adverse 
long-term outcomes [14], but, to the best of our knowl-
edge, this is one of the first studies to examine the effect 
of recurrent AKI in critically ill patients and during a sin-
gle hospitalization. We went on to examine risk factors 
for recurrent AKI and were not able to identify any, other 
than a trend for gender and ethnicity. This may reflect the 
fact that we only studied risk factors at baseline and upon 
development of the first AKI episode, whereas future or 
time-updated risk factors (e.g., new or recurrent sep-
sis, repeated exposures to nephrotoxins) are likely the 
strongest drivers of recurrent AKI. Alternatively, this 
may have been due to a lack of power given our relatively 
small sample size or the exclusion of certain very high-
risk populations (e.g., those with advanced heart failure 
or liver failure) from the overall population. A similar 
study examined predictors of recurrent AKI after renal 
transplantation [15] and was unable to identify any risk 
factors, while other studies have mostly focused on pre-
dictors of a second hospitalization with AKI, rather than 
a second episode during a single hospitalization [16].
Our overall results differ somewhat from other studies, 
which have highlighted the importance of AKI duration 
and especially transient AKI. Many of these studies have 
focused on less severely ill patients or have only included 
patients who survive hospitalization [17]. In contrast, our 
population of critically ill patients had multi-organ fail-
ure with sepsis and ARDS in addition to AKI, and the 
in-hospital mortality rate of this patient group was very 
high. While other studies have only focused on mortality 
as primary endpoint, we here report the influence of AKI 
duration on other relevant outcomes along with mortal-
ity while accounting for AKI severity and recurrent AKI 
status.
Potential limitations of our study include the very spe-
cific nature of our population, all of whom were critically 
ill adults with sepsis-associated ARDS who developed 
AKI. However, this is an extremely well-characterized 
population from a large randomized clinical trial, where 
a number of aspects of care including mechanical ventila-
tion and fluid management were protocolized, resulting 
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in less concern about variations in clinical care and the 
effect of these variations on outcomes. Furthermore, 
there has been much interest in the interplay of ARDS 
and AKI, which thought to be closely connected as part 
of multi-organ dysfunction, with the presence of both 
diseases associated with worse clinical outcomes [18]. 
Although more studies are needed to determine the 
direct effects of ARDS on AKI, our study focuses on a 
well-recognized and important clinical population. Out-
patient creatinine measurements were unfortunately not 
unavailable, but this is often the case the clinical settings, 
where many patients lack an outpatient baseline creati-
nine. As part of the study protocol, serum creatinine val-
ues were recorded for up to 48 h before study enrollment, 
which allowed us to use these serum creatinine values as 
baseline values and to calculate a rolling 48-h window for 
AKI ascertainment, rather than using an imputed base-
line or nadir serum creatinine as baseline. Our study is 
greatly strengthened by its richness and completeness in 
clinical variables obtained as part of a multicenter clini-
cal trial as well as the racial/ethnic diversity of the study 
population.
Conclusions
In summary, we evaluated the association of AKI dura-
tion on outcomes in a cohort of critically ill patients with 
sepsis-associated ARDS. We found no differences in out-
comes in patients with short duration AKI compared 
to those with medium duration AKI, while persistent 
AKI was associated with worse outcomes. Compared to 
patients with persistent AKI or who died during AKI, 
patients with resolving AKI were less likely to have oligu-
ria, moderate/severe ARDS or higher serum creatinine 
on the day of AKI. We found that recurrent AKI was 
associated with poorer clinical outcomes, but no clini-
cal factors at baseline could predict the development of 
recurrent AKI. Our findings suggest that the ideal popu-
lation for AKI clinical trials in patients with ARDS may 
be those with persistent AKI or at increased risk of per-
sistent AKI, since the impact of short and medium dura-
tion AKI on clinical outcomes is modest.
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